The Medical Advisor

Medically Reviewed by: OneDayMD Editorial Team Last Updated: May 2026 Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) has treated a large volume of cancer patients using repurposed drugs since 2023 and has documented outcomes publicly on Substack and X. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and dru...

Abstract Background: Drug repurposing has emerged as a strategy in oncology to identify low-cost, widely available agents with potential anticancer activity. Antiparasitic benzimidazoles (fenbendazole, mebendazole) and the macrocyclic lactone ivermectin have been proposed as adjunctive therapies in breast cancer based on preclinical mechanistic data and anecdotal clinical reports. Interest has grown within integrative oncology communities, particularly for advanced or treatment-resistant disease. Objective: To compile and summarize reported case experiences describing the use of fenbendazole, ivermectin, and mebendazole in patients with breast cancer, and to outline proposed biological mechanisms and current evidence gaps. Methods: Publicly available case reports, patient testimonials, and practitioner-shared clinical narratives involving breast cancer patients who used fenbendazole, ivermectin, or mebendazole were reviewed and categorized by disease stage, concurrent conventiona...